生物化学杨洋信号传导.ppt

* * * * * * * * Janus古罗马神话中的两面神 * * Initial studies with small molecules designed to inhibit the tyrosine kinase (TK) domain of the EGFR, such as gefitinib (Iressa) and erlotinib (Tarceva), demonstrated biologic and clinical activity in only a relatively limited subset of lung cancers.[1] Further investigation demonstrated that the highest response rates were seen in patients with somatic mutations within the EGFR-TK domain, 90% of which involve a relatively small number of amino acids within a specific region (exons 19 and 21). * (六) TGF-β途径 （1）胞外信息：TGF-β、活化素、骨形态发生蛋白等 （2）膜受体：TβRⅠ和Ⅱ 受体具有Ser/T